Although previous studies have confirmed the benefit of antiretroviral use for pre and post exposure prophylaxis in sexually transmitted HIV, little is known about prophylactic effect in injectable drug users. A randomised, double-blind, placebo-controlled phase 3 trial published in the Lancet journal enrolled 2413 HIV negative subjects from 17 drug-treatment clinics in Bangkok, Thailand and randomized them to daily Tenofovir or placebo. Results revealed a 48.9% reduction in the incidence of HIV. Are you aware of the 2012 CDC recommendations on the use of pre-exposure prophylaxis to limit HIV transmission?
Please follow the link below for more detailed information on this study: